MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-16-2023
Athersys Cash and Cash Equivalents 2011-2026 | ATHX
Annual Cash and Cash Equivalents Athersys
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 37.4 M | 51.5 M | 35 M | 51.1 M | 29.3 M | 14.8 M | 23 M | 26.1 M | 31.9 M | 25.5 M | 8.78 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 51.5 M | 8.78 M | 30.4 M |
Quarterly Cash and Cash Equivalents Athersys
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.02 M | 1.8 M | 3.12 M | 9.04 M | 13.8 M | 13.4 M | 21.8 M | 37.4 M | 49.7 M | 56.7 M | 64.2 M | 51.5 M | 51.5 M | 51.5 M | 51.5 M | 35 M | 35 M | 35 M | 35 M | 51.1 M | 51.1 M | 51.1 M | 51.1 M | 29.3 M | 29.3 M | 29.3 M | 29.3 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 23 M | 23 M | 23 M | 23 M | 26.1 M | 26.1 M | 26.1 M | 26.1 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M | 25.5 M | 25.5 M | 25.5 M | 25.5 M | 8.78 M | 8.78 M | 8.78 M | 8.78 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64.2 M | 1.02 M | 28.6 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M |  USA |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adaptimmune Therapeutics plc
ADAP
|
144 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
145 M | $ 80.34 | - | $ 1.55 B | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M |  Canada |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.84 | 1.96 % | $ 4.58 M |  China |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | China |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Adagene
ADAG
|
75.2 M | $ 2.67 | - | $ 150 M | China |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.57 | - | $ 8.59 B |  Australia |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
89.4 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
42.9 M | $ 1.5 | - | $ 281 M | USA |
 |
Aptose Biosciences
APTO
|
6.15 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Ascendis Pharma A/S
ASND
|
560 M | $ 222.03 | - | $ 5 B |  Danmark |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
9.76 B | $ 110.34 | - | $ 27.2 B | Germany |
 |
Cabaletta Bio
CABA
|
193 M | $ 2.44 | - | $ 2.85 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
220 M | - | -6.81 % | $ 3.04 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
4.88 M | - | 17.91 % | $ 11.1 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 8.97 | - | $ 1.44 B | Britain |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Athira Pharma
ATHA
|
48.4 M | - | - | $ 269 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 4.22 | - | $ 9.18 B |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.46 | - | $ 373 M | Britain |
 |
Compugen Ltd.
CGEN
|
7.8 M | $ 1.71 | - | $ 153 M | Israel |
 |
Amneal Pharmaceuticals
AMRX
|
111 M | $ 14.52 | - | $ 4.49 B | USA |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |